Literature DB >> 27020700

Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.

Tae Hun Kim1, Hee Seung Kim2, Tae-Joong Kim3, Suk-Joon Chang4, Dae-Yeon Kim5, Sang-Young Ryu1, Byoung-Gie Kim3, Young-Tak Kim6, Duk-Soo Bae3, Hee-Sug Ryu4, Joo-Hyun Nam6.   

Abstract

OBJECTIVE: To investigate whether the number of lymph nodes obtained during lymphadenectomy affects the survival of patients with intermediate- or high-risk endometrioid-type endometrial cancer.
METHODS: A total of 476 patients who were diagnosed with FIGO stage IB to IIIC2 endometrioid adenocarcinoma through surgical staging, including hysterectomy and pelvic lymphadenectomy with or without paraaortic lymphadenectomy between 2000 and 2013 were retrospectively enrolled from four tertiary centers in Korea. Sentinel lymph node mapping was not performed in any patient. The number of nodes obtained and positive nodes, was extracted from pathologic report.
RESULTS: Paraaortic lymphadenectomy was performed in 298 (62.6%) patients and 164 (34.4%) had stage IIIC disease. The isolated paraaortic lymph node metastasis rate decreased as the number of pelvic nodes obtained increased. In the total study population, an increase of negative pelvic and paraaortic nodes was associated with improved recurrence-free survival (RFS) and overall survival (OS) independent of other prognostic factors. In the node-positive group, an increase of negative pelvic nodes was an independent prognostic factor for RFS [hazard ratio (HR), 0.946; 95% confidence interval (CI), 0.906-0.988] and OS [HR, 0.907; 95% CI, 0.849-0.968]. In stage IIIC2 patients, 14 or less negative pelvic nodes was associated with poor RFS and OS.
CONCLUSIONS: Removing as many pelvic nodes as possible is required to warrant accurate nodal staging and improve survival in patients with intermediate- or high-risk endometrial cancer. Sentinel lymph node mapping can be a resolution to minimize lymph node dissection without compromising staging accuracy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial cancer; Lymph node excision; Lymphatic metastasis; Neoplasm staging; Prognosis

Mesh:

Year:  2016        PMID: 27020700     DOI: 10.1016/j.ygyno.2016.03.031

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.

Authors:  Brooke A Schlappe; Amy L Weaver; Jennifer A Ducie; Ane Gerda Zahl Eriksson; Sean C Dowdy; William A Cliby; Gretchen E Glaser; Robert A Soslow; Kaled M Alektiar; Vicky Makker; Nadeem R Abu-Rustum; Andrea Mariani; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2018-08-31       Impact factor: 5.482

2.  Differential Impact of Systemic Lymphadenectomy Upon the Survival of Patients with Type I vs Type II Endometrial Cancer: A Retrospective Observational Cohort Study.

Authors:  Jie Xu; Can Chen; Jing Xiong; Hua Linghu
Journal:  Cancer Manag Res       Date:  2020-11-30       Impact factor: 3.989

3.  Role of lymphadenectomy in intermediate-risk endometrial cancer: a matched-pair study.

Authors:  Pluvio J Coronado; Agnieszka Rychlik; Maria A Martínez-Maestre; Laura Baquedano; María Fasero; Aida García-Arreza; Sara Morales; Daniel M Lubian; Ignacio Zapardiel
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

4.  Aortic utero-ovarian sentinel nodes and left infrarenal aortic lymph node dissection by ICG supported navigation.

Authors:  Rainer Kimmig; Peter Rusch; Paul Buderath; Bahriye Aktas
Journal:  Gynecol Oncol Rep       Date:  2017-02-09

5.  Quantitative Measurement of Progesterone Receptor Immunohistochemical Expression to Predict Lymph Node Metastasis in Endometrial Cancer.

Authors:  Yu-Yang Hsiao; Hung-Chun Fu; Chen-Hsuan Wu; Jui Lan; Yu-Che Ou; Ching-Chou Tsai; Hao Lin
Journal:  Diagnostics (Basel)       Date:  2022-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.